Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of MONOVIR vs LAGEVRIO (molnupiravir 200 mg) under fasting conditions
TCTR20220508005Phase 1Not yet recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of molnupiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Government Pharmaceutical Organization. Planned start May 2022; status: not yet recruiting.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220508005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220508005.